Page 18 - தலை ஆஃப் முதலீட்டாளர் உறவுகள் பெருநிறுவன தகவல்தொடர்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

and Chair of the Steering Committee for SOS-AMI, commented: P2Y 12 receptor antagonists have been used in the treatment of millions of patients globally, and their safety and efficacy profiles are well established. Despite the success of chronic treatment with this class and other effective interventions, patients are still suffering recurrent heart attacks. The idea for patients to self-inject early in the onset of symptoms is truly innovative. The subcutaneous route of administration could overcome the onset delay observed with oral compounds from the same class. To be effective, any antithrombotic treatment for use at the onset of AMI symptoms should be rapidly absorbed and potent, acting quickly to inhibit thrombus formation at an early stage. Inhibition should be reversed after a few hours to avoid interfering with later patient management decisions. It must also have an appropriate safety profile for use prior to formal diagnosis of AMI. Selatogrel has the potential to s

Switzerland generalUnited statesUnited kingdomHarvard universityBoston latin schoolMartine clozelAndrewc weissColl cardiolGuy braunsteinJean paul clozelDeepakl bhattMary mooneyCardiovascular coordinating centerHead of investor relations corporate communicationsTrinity college dublinUnited kingdom heart attack study collaborative group